Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1671161 | 0.88 | KDM4E (0.52) | L3MBTL1ALDH1A1NPC1TSHRMAPK1 | |
| SCHEMBL3084388 | 0.86 | L3MBTL1 (0.50) | L3MBTL1ALDH1A1TSHRHPGDMEN1 | |
| SCHEMBL12113209 | 0.86 | NPC1 (0.61) | L3MBTL1ALDH1A1NPC1TSHRHPGD | |
| SCHEMBL6160250 | 0.85 | PTPN1 (0.55) | L3MBTL1ALDH1A1TSHRMAPK1MEN1 | |
| SCHEMBL4724490 | 0.84 | L3MBTL1 (0.58) | L3MBTL1ALDH1A1NPC1TSHRHPGD | |
| SCHEMBL4731077 | 0.84 | NPC1 (0.59) | L3MBTL1ALDH1A1NPC1TSHRHPGD | |
| SCHEMBL16453663 | 0.84 | L3MBTL1 (0.58) | L3MBTL1ALDH1A1NPC1TSHRHPGD | |
| SCHEMBL11451808 | 0.83 | PTPN1 (0.57) | L3MBTL1ALDH1A1TSHRMAPK1MEN1 | |
| SCHEMBL25270601 | 0.83 | KDM4E (0.50) | L3MBTL1ALDH1A1NPC1TSHRHPGD | |
| SCHEMBL1313733 | 0.83 | L3MBTL1 (0.74) | L3MBTL1ALDH1A1NPC1HPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 422 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040013734-A1 | Mixture of water insoluble drug and polymer | PFIZER INC. | 2004-01-22 | — | — | US | claimed |
| WO-2001055109-A1 | AROMATIC AMIDES ACTING ON MELANOCORTIN RECEPTORS | MELACURE THERAPEUTICS AB (SE) | 2001-08-02 | — | — | WO | claimed |
| EP-1027886-A2 | Pharmaceutical solid dispersions | Pfizer Products Inc. (US) | 2000-08-16 | — | — | EP | claimed |
| US-20260132127-A1 | NOVEL SPIRO COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2026-05-14 | — | — | US | disclosed |
| EP-4729052-A1 | SUSTAINED RELEASE DOSAGE FORM FOR LOW SOLUBILITY COMPOUND TETRAHYDROCANNABINOL AND METHODS FOR PREPARING OF THIS SUSTAINED RELEASE DOSAGE FORM | Emoviar PharmaCon GmbH (DE) | 2026-04-22 | — | — | EP | disclosed |
| EP-4729049-A1 | SUSTAINED RELEASE DOSAGE FORM FOR LOW SOLUBILITY COMPOUND AXITINIB AND METHODS FOR PREPARING OF THIS SUSTAINED RELEASE DOSAGE FORM | Emoviar PharmaCon GmbH (DE) | 2026-04-22 | — | — | EP | disclosed |
| US-12599610-B2 | Solid dosage formulations of an orexin receptor antagonist | MERCK SHARP & DOHME LLC (US) | 2026-04-14 | — | — | US | disclosed |
| EP-3725778-B2 | FORMULATIONS OF ENZALUTAMIDE | MEDIVATION PROSTATE THERAPEUTICS LLC (US) | 2026-01-07 | — | — | EP | disclosed |
| US-12502357-B2 | Formulations of enzalutamide | ASTELLAS PHARMA INC. (JP) | 2025-12-23 | — | — | US | disclosed |
| US-12447128-B2 | Formulations of enzalutamide | ASTELLAS PHARMA INC. (JP) | 2025-10-21 | — | — | US | disclosed |
| US-20250228840-A1 | METHODS OF TREATING SJÖGREN-LARSSEN SYNDROME | ALDEYRA THERAPEUTICS, INC. | 2025-07-17 | — | — | US | disclosed |
| US-4753956-A | Hypoglycemic 5-substituted oxazolidine-2,4-diones | PFIZER INC. (US) | 1988-06-28 | — | — | US | disclosed |
| US-4689336-A | Hypoglycemic 5-substituted oxazolidine 2,4-diones | PFIZER INC. (US) | 1987-08-25 | — | — | US | disclosed |
| US-4565820-A | ANTIDIABETIC AGENTS | PFIZER INC. (US) | 1986-01-21 | — | — | US | disclosed |
| US-4431810-A | HYPOGLYCEMIC AGENTS | PFIZER INC. (US) | 1984-02-14 | — | — | US | disclosed |
| US-4342771-A | Hypoglycemic 5-substituted oxazolidine-2,4-diones | PFIZER INC. (US) | 1982-08-03 | — | — | US | disclosed |
| US-4181658-A | Certain nicotinamido-n-benzoic acid derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-01-01 | — | — | US | disclosed |
| US-4157395-A | TREATMENT OF DIABETES | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-06-05 | — | — | US | disclosed |
| US-3987172-A | HYPOGLYCEMIC AGENTS | PFIZER INC. (US) | 1976-10-19 | — | — | US | disclosed |
| US-3944524-A | ORAL HYPOGLYCEMIC AGENTS | PFIZER INC. (US) | 1976-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12599610-B2 | Solid dosage formulations of an orexin receptor antagonist | CRH, HCRTR2, HCRTR1 | L3MBTL1 4591/4885ALDH1A1 3659/4885NPC1 1147/4885 |
| US-20040013734-A1 | Mixture of water insoluble drug and polymer | ABCG2, ABCB1, ABCB11 | L3MBTL1 4425/4885ALDH1A1 2151/4885NPC1 737/4885 |
| US-12502357-B2 | Formulations of enzalutamide | AR, KLK3, NR5A1 | L3MBTL1 2956/4885ALDH1A1 1743/4885NPC1 1762/4885 |
| US-20260132127-A1 | NOVEL SPIRO COMPOUND | TRHR, NR3C2, THRB | L3MBTL1 3822/4885ALDH1A1 1063/4885NPC1 457/4885 |
| US-20250228840-A1 | METHODS OF TREATING SJÖGREN-LARSSEN SYNDROME | SSB, HRH2, ASAH2 | L3MBTL1 4768/4885ALDH1A1 1676/4885NPC1 1323/4885 |
| US-12447128-B2 | Formulations of enzalutamide | AR, KLK3, NR5A1 | L3MBTL1 2956/4885ALDH1A1 1743/4885NPC1 1762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.